Literature DB >> 33148545

Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017.

Lina Wang1,2, Feng Ze3, Jun Li4, Lan Mi5, Bing Han6, Huan Niu7, Na Zhao8.   

Abstract

OBJECTIVE: This study aimed to estimate the global burden of atrial fibrillation/atrial flutter (AF/AFL).
METHODS: We retrieved data from the Global Health Data Exchange query tool and estimated the age-standardised rates (ASRs) of prevalence, incidence and disability-adjusted life-years (DALYs) of AF/AFL, as well as the population attributable fraction (PAF) of risk factors contributing to DALYs. ASRs and sociodemographic index (SDI) were assessed using Pearson's correlation coefficients.
RESULTS: In 2017, there were 37.6 million (95% uncertainty interval (UI) 32.5 to 42.6 million) individuals with AF/AFL globally. The prevalence rates increased with increased SDI values in most regions for all years. Men had a higher prevalence than women across all regions except for China. From 1990 to 2017, global prevalence rate decreased by 5.08% (95% UI -6.24% to -3.82%), with the largest decrease noted in the region with high SDI values. The global DALYs rate declined by 2.53% (95% UI -4.16 to -0.29). PAF of elevated systolic blood pressure for attributable DALYs accounted for the highest percentage, followed by high body mass index, alcohol use, high-sodium diet, smoking and lead exposure.
CONCLUSIONS: Although the ASRs of prevalence, incidence and DALYs decreased from 1990 to 2017, the absolute number of patients with AF/AFL, annual number of new AF/AFL cases and DALYs lost due to AF/AFL increased. This indicates that the burden of AF/AFL is likely to remain high. Systematic surveillance is needed to better identify and manage AF/AFL so as to prevent its various risk factors and complications. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  atrial fibrillation; atrial flutter; epidemiology

Mesh:

Substances:

Year:  2020        PMID: 33148545     DOI: 10.1136/heartjnl-2020-317656

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  CXCR4 and TYROBP mediate the development of atrial fibrillation via inflammation.

Authors:  Yan-Fei Zhang; Ling-Bing Meng; Meng-Lei Hao; Xing-Yu Li; Tong Zou
Journal:  J Cell Mol Med       Date:  2022-05-23       Impact factor: 5.295

2.  Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy.

Authors:  Mette Søgaard; Flemming Skjøth; Peter B Nielsen; Jesper Smit; Michael Dalager-Pedersen; Torben B Larsen; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2022-05-02

3.  Heart Watch Study: protocol for a pragmatic randomised controlled trial.

Authors:  Sanket S Dhruva; Nilay D Shah; Sreekanth Vemulapalli; Abhishek Deshmukh; Alexis L Beatty; Ginger M Gamble; James V Freeman; James P Hummel; Jonathan P Piccini; Joseph G Akar; Keondae Ervin; Kristine L Arges; Lindsay Emanuel; Peter A Noseworthy; Tiffany Hu; Victoria Bartlett; Joseph S Ross
Journal:  BMJ Open       Date:  2021-12-30       Impact factor: 3.006

4.  Causal effects of atrial fibrillation on brain white and gray matter volume: a Mendelian randomization study.

Authors:  Sehoon Park; Soojin Lee; Yaerim Kim; Semin Cho; Kwangsoo Kim; Yong Chul Kim; Seung Seok Han; Hajeong Lee; Jung Pyo Lee; Soryoung Lee; Eue-Keun Choi; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Dong Ki Kim
Journal:  BMC Med       Date:  2021-11-24       Impact factor: 8.775

5.  Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study.

Authors:  Konsta Teppo; Jussi Jaakkola; K E Juhani Airaksinen; Fausto Biancari; Olli Halminen; Jukka Putaala; Pirjo Mustonen; Jari Haukka; Juha Hartikainen; Alex Luojus; Mikko Niemi; Miika Linna; Mika Lehto
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

6.  One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.

Authors:  Ayman Hammoudeh; Yousef Khader; Ramzi Tabbalat; Yahya Badaineh; Nazih Kadri; Haneen Shawer; Eyas Al-Mousa; Rasheed Ibdah; Batool A Shawer; Imad A Alhaddad
Journal:  Int J Vasc Med       Date:  2022-04-13

7.  Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation.

Authors:  Ruopeng Tan; Haixu Yu; Xu Han; Yang Liu; Xiaolei Yang; Yun-Long Xia; Xiaomeng Yin
Journal:  Front Cardiovasc Med       Date:  2021-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.